$25.4
+0.05
(+0.2%)▲
0.16%
Downside
Day's Volatility :0.16%
Upside
0.0%
13.19%
Downside
52 Weeks Volatility :14.04%
Upside
0.97%
Period | Harrow Inc | Index (Russel 2000) |
---|---|---|
3 Months | 1.24% | 0.0% |
6 Months | 3.89% | 0.0% |
1 Year | 4.96% | 0.0% |
3 Years | -4.01% | -22.3% |
Market Capitalization | 247.5M |
Dividend Yield | 0.0% |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 44.84% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 41.4M | ↑ 54.52% |
Net Income | 14.6M | ↓ 222.03% |
Net Profit Margin | 35.35% | ↑ 80.11% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 51.2M | ↑ 23.67% |
Net Income | -2.6M | ↓ 117.72% |
Net Profit Margin | -5.07% | ↓ 40.42% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 48.9M | ↓ 4.48% |
Net Income | -3.4M | ↑ 31.91% |
Net Profit Margin | -7.0% | ↓ 1.93% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 72.5M | ↑ 48.3% |
Net Income | -18.0M | ↑ 426.67% |
Net Profit Margin | -24.85% | ↓ 17.85% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 88.6M | ↑ 22.24% |
Net Income | -14.1M | ↓ 21.77% |
Net Profit Margin | -15.9% | ↑ 8.95% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 130.2M | ↑ 46.95% |
Net Income | -24.4M | ↑ 73.3% |
Net Profit Margin | -18.75% | ↓ 2.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 26.1M | ↑ 28.4% |
Net Income | -6.6M | ↓ 729.67% |
Net Profit Margin | -25.45% | ↓ 30.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 33.5M | ↑ 28.22% |
Net Income | -4.2M | ↓ 36.34% |
Net Profit Margin | -12.64% | ↑ 12.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 34.3M | ↑ 2.38% |
Net Income | -4.4M | ↑ 3.83% |
Net Profit Margin | -12.81% | ↓ 0.17% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 36.4M | ↑ 6.1% |
Net Income | -9.1M | ↑ 108.34% |
Net Profit Margin | -25.16% | ↓ 12.35% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 34.6M | ↓ 4.86% |
Net Income | -13.6M | ↑ 48.28% |
Net Profit Margin | -39.22% | ↓ 14.06% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 48.9M | ↑ 41.5% |
Net Income | -6.5M | ↓ 52.28% |
Net Profit Margin | -13.23% | ↑ 25.99% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 49.5M | ↑ 106.76% |
Total Liabilities | 24.7M | ↑ 15.95% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 59.1M | ↑ 19.48% |
Total Liabilities | 31.7M | ↑ 28.21% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 57.5M | ↓ 2.73% |
Total Liabilities | 30.6M | ↓ 3.22% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 98.3M | ↑ 71.08% |
Total Liabilities | 87.4M | ↑ 185.19% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 157.0M | ↑ 59.69% |
Total Liabilities | 130.1M | ↑ 48.9% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 311.8M | ↑ 98.54% |
Total Liabilities | 241.8M | ↑ 85.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 217.5M | ↑ 38.51% |
Total Liabilities | 196.0M | ↑ 50.59% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 224.0M | ↑ 2.98% |
Total Liabilities | 201.9M | ↑ 3.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 286.1M | ↑ 27.71% |
Total Liabilities | 210.7M | ↑ 4.32% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 311.8M | ↑ 8.98% |
Total Liabilities | 241.8M | ↑ 14.76% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 295.1M | ↓ 5.35% |
Total Liabilities | 235.3M | ↓ 2.66% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 306.2M | ↑ 3.76% |
Total Liabilities | 248.5M | ↑ 5.58% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 687.0K | ↓ 107.8% |
Investing Cash Flow | -2.2M | ↑ 128.82% |
Financing Cash Flow | 4.1M | ↓ 16.21% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 950.0K | ↑ 38.28% |
Investing Cash Flow | -1.8M | ↓ 16.64% |
Financing Cash Flow | -1.0M | ↓ 124.35% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.1M | ↓ 215.79% |
Investing Cash Flow | -981.0K | ↓ 46.48% |
Financing Cash Flow | 1.4M | ↓ 242.45% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.1M | ↓ 562.0% |
Investing Cash Flow | -18.7M | ↑ 1804.79% |
Financing Cash Flow | 51.5M | ↑ 3491.77% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7M | ↓ 66.45% |
Investing Cash Flow | -1.7M | ↓ 90.67% |
Financing Cash Flow | 54.1M | ↑ 5.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.2M | ↑ 121.28% |
Investing Cash Flow | -131.0M | ↑ 2619300.0% |
Financing Cash Flow | 62.2M | ↑ 12.96% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.6M | ↓ 155.59% |
Investing Cash Flow | -1.2M | ↓ 99.05% |
Financing Cash Flow | 189.0K | ↓ 99.7% |
Sell
Neutral
Buy
Harrow Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Harrow Inc | 0.79% | 3.89% | 4.96% | -4.01% | 2.06% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Harrow Inc | NA | NA | NA | 0.0 | 0.45 | 0.0 | 0.0 | NA |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Harrow Inc | Buy | $247.5M | 2.06% | NA | 0.0% |
Insights on Harrow Inc
Revenue is up for the last 2 quarters, 34.58M → 48.93M (in $), with an average increase of 29.3% per quarter
Netprofit is up for the last 2 quarters, -13.56M → -6.47M (in $), with an average increase of 109.6% per quarter
harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
Organization | Harrow Inc |
Employees | 22 |
CEO | |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$25.40
+0.2%
Keyarch Acquisition Corp
$25.40
+0.2%
Connexa Sports Technologies Inc
$25.40
+0.2%
Us Value Etf
$25.40
+0.2%
First Wave Biopharma Inc
$25.40
+0.2%
Global X Msci Next Emerging
$25.40
+0.2%
Fat Projects Acquisition Corp
$25.40
+0.2%
Capital Link Global Fintech
$25.40
+0.2%
Applied Uv Inc
$25.40
+0.2%